Drug Type Small molecule drug |
Synonyms 리바로하이정 |
Action antagonists, inhibitors, blockers |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), L-type calcium channel blockers(Voltage-gated L-type calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (24 Sep 2025), |
Regulation- |
Molecular FormulaC24H29N5O3 |
InChIKeyACWBQPMHZXGDFX-QFIPXVFZSA-N |
CAS Registry137862-53-4 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Essential Hypertension | South Korea | 24 Sep 2025 | |
| Primary hypercholesterolemia | South Korea | 24 Sep 2025 |





